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Abstract
Introduction: A proportion of patients receiving infliximab have antibodies toward infliximab (ATI), which are
associated with increased risk of infusion reaction and reduced response to treatment. We studied the association
of infliximab concentration at treatment initiation and development of ATI as well as the association of the
presence of ATI and maintenance of infliximab.
Methods: All patients with rheumatoid arthritis (RA) or spondyloarthritis (SpA) receiving infliximab beginning in
December 2005 were retrospectively followed until January 2009 or until infliximab discontinuation. Trough
serum infliximab and ATI concentrations were measured at each visit. The patients were separated into two
groups: ATIpos if ATI were detected at least once during the follow-up period and ATIneg otherwise. Repeated
measures analysis of variance was used to study the association of infliximab concentration at treatment
initiation and the development of ATI. Maintenance of infliximab in the two groups was studied by using
Kaplan-Meier curves.
Results: We included 108 patients: 17 with RA and 91 with SpA. ATI were detected in 21 patients (19%). The
median time to ATI detection after initiation of infliximab was 3.7 months (1.7 to 26.0 months). For both RA and
SpA patients, trough infliximab concentration during the initiation period was significantly lower for ATIpos than
ATIneg patients. RA patients showed maintenance of infliximab at a median of 19.5 months (5.0 to 31.0 months)
and 12.0 months (2.0 to 24.0 months) for ATIneg and ATIpos groups, respectively (P = 0.08). SpA patients showed
infliximab maintenance at a median of 16.0 months (3.0 to 34.0 months) and 9.5 months (3.0 to 39.0 months) for
ATIneg and ATIpos groups, respectively (P = 0.20). Among SpA patients, those who were being treated
concomitantly with methotrexate had a lower risk of developing ATI than patients not taking methotrexate (0 of
14 patients (0%) vs. 25 of 77 patients (32%); P = 0.03).
Conclusions: High concentrations of infliximab during treatment initiation reduce the development of ATI, and the
absence of ATI may be associated with prolonged maintenance of infliximab. Thus, trough serum infliximab
concentration should be monitored early in patients with rheumatic diseases.
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Infliximab, a chimeric mAb targeting TNFa,i su s e dt o
treat rheumatoid arthritis (RA), spondyloarthritis (SpA)
and inflammatory bowel diseases. Its efficacy and safety
have been evaluated in selected patients in pivotal clini-
cal trials [1-3], but predictive factors regarding its main-
tenance in the postmarketing clinical setting have not
been reported. Because of its immunogenicity, infliximab
is responsible for the development of antibodies toward
infliximab (ATI), which is associated with increased risk
of treatment failure. In RA, the development of ATI is
inversely proportional to the dosage of infliximab [1],
and low trough serum infliximab concentration 1.5
months after initiation is associated with the develop-
ment of ATI [4]. Moreover, ATI are associated with
increased risk of infusion reactions and decreased
response to infliximab [4,5]. Trough serum infliximab
concentration has been measured in SpA in only two
studies. De Vries et al. [6] found that treatment failure
is associated with low serum concentration and that the
development of ATI is associated with undetectable
trough infliximab concentration, reduced response to
treatment and increased risk of infusion reactions. In
contrast, Krzysiek et al. [7] did not find any association
of trough infliximab concentration and response to
treatment. Therefore, the relationships among infliximab
concentration, development of ATI and response to
treatment are less clear in SpA than in RA. Moreover,
no study has focused on the temporal relationship
between trough infliximab concentration and develop-
ment of ATI.
We studied the association of trough serum infliximab
concentration measured at treatment initiation and the
development of ATI in a retrospective cohort with
inflammatory rheumatic diseases. We also studied the
association of ATI, infusion-related reactions and main-
tenance of infliximab.
Materials and methods
Patients
Patients with RA and patients with SpA whose inflixi-
mab treatment was started between December 2005 and
January 2009 or until infliximab discontinuation were
retrospectively included. Demographic characteristics,
mean disease duration and concomitant treatment with
methotrexate (MTX) or prednisone were recorded
before infliximab initiation. RA patients received 3 mg/
kg infliximab intravenously (rounded in the 100-mg vial)
at weeks 0, 2, 6 and 14 and every 8 weeks thereafter,
and SpA patients received 5 mg/kg infliximab (rounded
in the 100-mg vial) at weeks 0, 2, 6 and 12 and every 6
weeks thereafter. The time and circumstances of discon-
tinuation were recorded. The treatment protocol was in
accordance with the guidelines of the French Society of
Rheumatology for the use of infliximab [8,9]. Ethical
approval and informed consent were not sought in this
retrospective analysis of routine patients, which is in
accordance with institutional guidelines.
Clinical measurements
Before proceeding with the first infusion (baseline) and
at each subsequent infusion, patients were asked about
any adverse events since the previous visit and under-
went a physical examination and urine analysis to rule
out any concomitant infection. At each visit, the Disease
Activity Score in 28 joints was measured for RA patients
and the Bath Ankylosing Spondylitis Disease Activity
Index (BASDAI) was used to assess disease activity in
SpA patients. Blood samples were obtained 48 hours
before each infusion for routine measurement of ery-
throcyte sedimentation rate (ESR) and C-reactive pro-
tein level (CRP).
Infliximab serum and ATI concentrations
Serum samples were obtained just before each infusion
for infliximab concentration measurement and ATI
detection within the framework of routine therapeutic
drug monitoring. The samples were not drawn specifi-
cally for this study, which was performed retrospectively.
Infliximab concentrations were measured by ELISA as
described previously [10]. Serum concentration of ATI
was measured by double-antigen ELISA on the basis of
capture by infliximab-coated microplates and detection
by peroxidase-conjugated infliximab [11]. This assay was
standardised by the use of a mouse mAb against human
immunoglobulin G. The positive threshold of detection
was 0.07 mg/L. Because of the interference of circulating
infliximab, only sera with infliximab concentration < 2
mg/L were tested. Patients were separated into two
groups: ATIpos if ATI were detected at least once during
follow-up and ATIneg otherwise.
Dose adjustment
Infliximab dose could be adapted after the fourth infu-
sion. The decision to increase, decrease or discontinue
infliximab took into account the disease activity assess-
ment on the one hand and infliximab trough concentra-
tion on the other hand. The principle underlying this
drug monitoring procedure was previously described
[12].
Statistical analysis
Baseline characteristics of ATIpos and ATIneg groups
were compared by using Student’s t-test or a c
2 test.
Repeated measures analysis of variance was used to
study the association of infliximab concentration during
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tenance of infliximab was studied by using Kaplan-
Meier curves, and groups were compared by using a
logrank test. Statistical analysis involved use of R version
2.7.2 software [13]. P < 0.05 was considered statistically
significant. Results are presented as medians (full
ranges) unless otherwise stated.
Results
Baseline characteristics of patients
We included 108 patients: 17 with RA and 91 with
SpA. ATI, which were undetectable in all patients
before the initiation of infliximab therapy, were
detected in 21 patients (7 with RA and 14 with SpA)
during follow-up. The proportion of ATIpos patients
was higher among those with RA than in patients with
SpA (41% vs. 15%, respectively; P =0 . 0 3 ) .T h eb a s e l i n e
characteristics of the patients are given in Table 1. The
ATIpos and ATIneg patients did not differ with regard
to age, body mass index, concomitant treatment with
prednisone or ESR or CRP level. For SpA patients, dis-
ease duration was longer, but not significantly so, for
the ATIpos group than for the ATIneg group. Median
time of ATI detection after initiation was 3.7 months
(1.7 to 26.0 months). For RA patients, the infliximab
dose was lower, but not significantly so, for the ATIpos
patients than for the ATIneg patients (Table 1 and Fig-
ure 1). For SpA patients, concomitant MTX treatment
was lower for ATIpos than for ATIneg patients (0 (0%)
of 14 vs. 25 (32%) of 77, respectively; P = 0.03) (Tables
1a n d2 ) .
Association of initial infliximab concentration and
development of ATI
Trough serum infliximab concentration during treatment
initiation (weeks 2 to1 4 )w a sl o w e rf o rA T I pos patients
than for ATIneg patients for both diseases, with the
difference being significant as early as week 2 (Table 3
Table 1 Baseline characteristics of the patients
a
RA (n = 17) SpA (n = 91)
Characteristics ATIpos (n = 7) ATIneg (n = 10) P value ATIpos (n = 14) ATIneg (n = 77) P value
Age, years 49 (28 to 65) 47 (36 to 64) 0.7 47 (36 to 73) 44 (14 to 76) 0.2
Body mass index, kg/m
2 25.9 (20.2 to 34.8) 23.5 (16.4 to 34.6) 0.5 24.8 (17.5 to 32.8) 26.1 (15.8 to 45.8) 0.1
Disease duration, years 6.0 (1 to 12) 10 (2 to 30) 0.07 8.9 (0 to 24) 5 (0 to 24) 0.3
Infliximab dose, mg/kg 3.0 (2.8 to 3.7) 3.6 (2.6 to 5.4) 0.09 4.9 (2.9 to 5.7) 5.0 (2.8 to 6.7) 0.4
Concomitant treatments
MTX, n (%) 3 (43) 6 (60) 0.8 0 (0) 25 (32) 0.03
Prednisone, n (%) 4 (57) 8 (80) 0.6 2 (14) 12 (16) 0.8
ESR, mm/hour 14 (7 to 58) 24 (2 to 114) 0.5 8 (2 to 54) 10 (1 to 89) 0.6
CRP, mg/L 10 (3 to 81) 16 (3 to 124) 0.9 3 (1 to 72) 5 (1 to 74) 0.9
aATI: antibodies toward infliximab; ATIpos: ATI detected at least once during follow-up; ATIneg: ATI not detected; RA: rheumatoid arthritis; SpA: spondyloarthritis;
MTX: methotrexate; ESR: erythrocyte sedimentation rate; CRP: C-reactive protein. Results are given as medians (ranges) unless otherwise indicated.
Figure 1 Initial infliximab dose for patients positive and
negative for antibodies toward infliximab (ATIpos and ATIneg,
respectively). Box plots show the medians and interquartile ranges,
and the whisker plots represent the 95th percentiles. Two patients
in the RA subgroup (open circles) received 5 mg/kg infliximab at
initiation because they were initially suspected of having psoriatic
arthritis. During follow-up, anticitrullinated protein antibodies were
detected in both patients, which explains their placement in the RA
subgroup. Two patients with SpA (open circles) received 3 mg/kg
infliximab at initiation because they had a peripheral form of the
disease and were therefore misclassified as having RA. ATI:
antibodies toward infliximab; ATIpos: ATI detected at least once
during follow-up; ATIneg: ATI not detected; RA: rheumatoid arthritis;
SpA: spondyloarthritis.
Table 2 Development of ATI by MTX treatment in RA and
SpA patients
a
RA (n = 17) SpA (n = 91)
MTX treatment ATIpos ATIneg P value ATIpos ATIneg P value
MTX+ 3 6 0 25
MTX- 4 4 0.8 14 52 0.03
aATI: antibodies toward infliximab; ATIpos: ATI detected at least once during
follow-up; ATIneg: ATI not detected; RA: rheumatoid arthritis; SpA:
spondyloarthritis; MTX: methotrexate. Data represent number of patients in
each category.
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was discontinued because of concomitant infection or
surgery, and ATI developed after infliximab therapy was
resumed.
Association of ATI, infusion reactions and maintenance of
infliximab
Among ATIpos patients, 11 (52%) had at least one infu-
sion-related reaction, as compared with only 1 (1%) in the
ATIneg group. The median interval between ATI detection
and infusion-related reactions was 42 days (0 to 702 days).
These infusion-related reactions were rashes, hyperther-
mia, chills, Quincke’s oedema and tachycardia. Among the
11 ATIpos patients who had a reaction to infusion, 4
required intravenous corticosteroids and intravenous anti-
histamines, and 2 required only oral antihistamines. One
patient developed Guillain-Barré syndrome that partially
improved after polyvalent immunoglobulin treatment. In
four patients, no treatment was given.
Eighteen (86%) of the ATIpos patients and forty-one
(47%) of the ATIneg patients discontinued infliximab
during follow-up. Events leading to treatment withdra-
wal significantly differed between the two groups (P <
0.001). In half of the 18 ATIpos patients, treatment
was stopped because of infusion-related reactions,
whereas in 31 (76%) of the 41 ATIneg patients treat-
ment was stopped because of treatment failure (Table
4). Infliximab was maintained longer, but not signifi-
cantly so, in ATIneg patients than in ATIpos patients
for both diseases (Figure 3). ATIneg and ATIpos
patients with RA showed maintenance of infliximab at
a median of 19.5 months (5.0 to 31.0 months) and
12.0 months (2.0 to 24.0 months), respectively (P =
0.08). ATIneg and ATIpos patients with SpA showed
maintenance of infliximab at a median of 16.0 months
(3.0 to 34.0 months) and 9.5 months (3.0 to 39.0
months), respectively (P = 0.20).
Association of trough infliximab concentration after
treatment initiation and maintenance of infliximab
The association of maintenance of infliximab with inflix-
imab concentration after treatment initiation is shown
in Figure 4. RA patients whose trough infliximab con-
centration at week 14 was above the median (concentra-
tion > 3.2 mg/L) and above the first quartile
(concentration > 0.05 mg/L) showed longer infliximab
maintenance than other patients, although not signifi-
cantly so (logrank = 0.06 and 0.2 respectively). For SpA
patients whose trough concentration at week 12 was
above the median (concentration > 13.7 mg/L), inflixi-
mab maintenance was no longer than that for other
patients (logrank = 0.9). However, infliximab mainte-
nance was longer for SpA patients with trough concen-
trations above the first quartile (concentration > 6.5 mg/
L; logrank = 0.05) than for other patients.
Discussion
Our study demonstrates that low trough infliximab con-
centration during treatment initiation is predictive of
immunisation against infliximab on the basis of the pre-
sence of ATI. Previous studies have reported an associa-
tion of low infliximab concentration 1.5 months after
initiation and the development of ATI [4]. We found
that more patients with than without ATI had a low
Figure 2 Infliximab concentrations at initiation in ATIpos and
ATIneg patients. Box plots show the medians and interquartile
ranges, and whisker plots represent the 95th percentiles. ATI:
antibodies toward infliximab; ATIpos: ATI detected at least once
during follow-up; ATIneg: ATI not detected; RA: rheumatoid arthritis;
SpA: spondyloarthritis.
Table 3 Trough infliximab concentration (mg/L) during infliximab initiation for ATIpos and ATIneg patients with RA and
SpA
a
RA (n = 17) SpA (n = 91)
Time after infliximab initiation ATIpos (n = 7) ATIneg (n = 10) P value ATIpos (n = 14) ATIneg (n = 77) P value
Week 2 7.7 (2.8 to 16.9) 27.2 (7.1 to 41.9) 0.002 25.0 (4.0 to 40.7) 35.8 (14.3 to 57.2) 0.003
Week 6 0.3 (0 to 6.2) 15.4 (2.7 to 35.0) 0.001 11.9 (0 to 24.2) 29.5 (3.4 to 69.0) < 0.001
Weeks 12 and 14 0 (0 to 0.03) 5.4 (0 to 21.9) 0.01 1.6 (0 to 13.5) 15.8 (0.7 to 47.3) < 0.001
aATI: antibodies toward infliximab; ATIpos: ATI detected at least once during follow-up; ATIneg: ATI not detected; RA: rheumatoid arthritis; SpA: spondyloarthritis.
Results are given as medians (ranges).
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their first infusion. Furthermore, in some cases, the
development of ATI occurred after a temporary discon-
tinuation of infliximab. Under a certain threshold con-
centration of infliximab, during treatment initiation or
even after a ‘therapeutic holiday’, patients may be at
high risk of immunisation against infliximab. ATI are
known to increase infliximab clearance, as previously
reported in SpA and inflammatory bowel diseases, and
could explain the nonresponse or loss of response in
some cases [14,15]. Our findings argue for early and
continuous monitoring of serum concentrations of mAb
i nd r u g ss u c ha si n f l i x i m a b .Further studies are needed
to support this hypothesis before it can be applied in
clinical practice.
As previously reported, development of ATI is asso-
ciated with poor maintenance of infliximab [5,6]. We
found that ATI developed during follow-up in 41% of
RA patients and 15% of SpA patients receiving inflixi-
mab. Our results are similar to those of previous studies
reporting ATI in 43% of RA patients and 29% of SpA
patients in the first year of treatment [5,6]. We found
that immunisation against infliximab occurs early after
treatment initiation, because we detected ATI in half of
the ATIpos patients before a median of 3.7 months of
treatment.
Immunogenicity of biopharmaceuticals is not
restricted to chimeric mAb. In a large cohort study of
RA patients treated with adalimumab, a fully human
mAb also targeting TNFa,B a r t e l d set al.[ 1 6 ]r e p o r t e d
that 76 (28%) of 272 patients developed antidrug antibo-
dies (ADAs) after three years of treatment. In their
study, ADAs were associated with a higher probability
of treatment failure and drug discontinuation compared
with ADA-negative patients. Immunisation appeared
soon after treatment started: 67% of cases were detected
during the first 28 weeks of therapy. The median time
until detection of ATI in our study was 3.7 months,
which is in good agreement with the results of the study
by Bartelds et al. [16].
The development of ATI was also associated with
increased risk of infusion reactions, as already reported
[4-6]. In our experience, half of ATIpos patients experi-
ence such reactions, often soon after the detection of
ATI, which leads to infliximab discontinuation.
Of note, because of drug intolerance, only 53% of our
RA patients received MTX with infliximab. This situa-
tion may account for the rather high frequency of
immunisation observed in our study. The role of MTX
in preventing ATI formation in RA was suspected by
Maini et al.[ 1 ]a n dB e n d t z e net al.[ 4 ] .I no u rs t u d y ,
ATI developed less often, although not significantly so,
in RA patients receiving infliximab and MTX than in
those receiving infliximab alone, but the small number
of patients (n = 17) prevents us from drawing any
Table 4 Causes of infliximab discontinuation in ATIpos
and ATIneg patients
a
Cause of discontinuation ATIpos (n = 18) ATIneg (n = 41)
Treatment failure
Primary failure 2 (11%) 23 (56%)
Secondary failure 3 (17%) 8 (20%)
Infusion reactions 9 (50%) 1 (2%)
Adverse events 1 (5.5%) 6 (15%)
Other 1 (5.5%) 2 (5%)
Lost to follow-up 2 (11%) 1 (2%)
aATI: antibodies toward infliximab; ATIpos: ATI detected at least once during
follow-up; ATIneg: ATI not detected. All data are number of patients (%).
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Figure 3 Infliximab maintenance according to ATI status in RA and SpA patients. ATI: antibodies toward infliximab; ATIpos: ATI detected at
least once during follow-up; ATIneg: ATI not detected.
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Page 5 of 7definite conclusions. To our knowledge, the present
study provides the first evidence of a significant associa-
tion of the use of MTX and a reduced risk of ATI
development in SpA. Breban et al. [17] tested MTX in
combination with infliximab in a subset of ankylosing
spondylitis patients receiving treatment with infliximab
by using an on-demand strategy. They showed a trend
toward fewer reactions to infusions in the group receiv-
ing MTX as compared with the group not receiving
MTX, although these results were not statistically signif-
icant. The fact that none of our SpA patients with MTX
have developed ATI suggests that MTX is a credible
factor in reducing immunisation and should be given in
combination with mAb.
High trough infliximab concentrations measured at the
end of treatment initiation (that is, before the fourth
infusion) seem to predict infliximab maintenance in both
RA and SpA. This result is in agreement with the find-
ings of our previous reports and suggests that early moni-
toring and dosage adjustment of underexposed patients
could improve long-term infliximab maintenance [18,19].
Conclusion
In summary, almost 20% of patients with rheumatic dis-
eases who received infliximab showed ATI during fol-
low-up, half of them before four months after treatment
initiation. High initial serum concentration of infliximab
reduces the development of ATI, and absence of ATI
seems to prolong maintenance of infliximab. Taken
together, these findings argue for early monitoring of
infliximab serum concentrations and should be con-
firmed in a prospective study.
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Figure 4 Maintenance of treatment by trough infliximab concentration after treatment initiation. RA patients were separated according
to (a) the median and (b) the first quartile of trough infliximab concentrations measured at week 14. SpA patients were separated according to
the (a) median and (b) the first quartile of trough infliximab concentrations measured at week 14. RA: rheumatoid arthritis; SpA:
spondyloarthritis.
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